Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 07:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline...
March 30, 2026 08:07 ET | Source: Scienture Holdings, Inc.

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for...
March 26, 2026 19:36 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..
March 25, 2026 02:00 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

In a phase 2 trial in Chinese people with T2D, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean weight reduction of up to of up to 9.8% ...
March 23, 2026 10:05 ET | Source: AdipoPharma

AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass

PITTSBURGH, March 23, 2026 (GLOBE NEWSWIRE) -- As GLP-1 therapies reshape obesity care, one biotech company is betting that the root cause of Type 2 diabetes isn’t only excessive weight but a...
March 12, 2026 08:00 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and...
February 18, 2026 09:03 ET | Source: Inspire

Inspire Launches New Type 1 and Type 2 Diabetes Subcommunities to Provide More Personalized Support and Education

Arlington, VA, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspire, the world’s largest free online community and support group for patients and caregivers, today announced the launch of two new dedicated...
January 22, 2026 04:17 ET | Source: Research and Markets

Global Needle-Free Diabetes Care Market Set to Reach USD 19.88 Billion by 2032, Revolutionizing Chronic Disease Management

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Needle Free Diabetes Care Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.The Needle Free Diabetes Care Market...
January 12, 2026 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing...
December 09, 2025 18:35 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif.,...